Is Surging Indivior PLC A Better Buy Than Struggling AstraZeneca plc?

Is AstraZeneca plc (LON: AZN) a better bet than Indivior PLC (LON: INDV)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Specialty pharmaceutical company Indivior (LSE: INDV) is rising today after the company issued an upbeat trading statement for the first half of the year. 

The company announced that trading for the period was ahead of expectations and management raised its guidance for the full year. 

Indivior now expects full-year 2015 revenue of between $935m to $965m, compared to its previous guidance of $850m to $880m. Net income is now expected to be in the region of $185m to $210m, compared to previous guidance of $130m to $155m.

First-half pre-tax profit fell to $199m, down from $327m as reported last year. 

Lack of diversification 

Even though Indivior’s results beat expectations, the company is still a one-trick pony. Indeed, with only one key treatment on the market at present, Indivior’s success is highly dependent upon the company’s ability to monetise its drug pipeline. 

Indivior’s key product is its opioid dependence treatment Suboxone Sublingual Film, the sales of which are falling as low-cost generic competitors break Indivior’s grip over the market. 

To a certain extent, AstraZeneca (LSE: AZN) is in the same position as Indivior. As Astra’s sales from legacy drugs are falling, the company is pinning its hopes on a raft on new treatments to help return the company to growth. 

However, as all investors know, diversification is key to achieving the best returns while minimising risk. And when it comes to treatment diversification, Astra’s broad offering should win over investors every time. 

It’s estimated that only 7% of new drugs make it from the initial discovery stage to commercial sale, which means that it’s crucial for pharmaceutical companies to hedge their bets by developing a broad range of new potential treatments. 

Astra has 222 new products currently under development. On the other hand, Indivior is expecting one new product roll-out every year from 2016 to 2020 — assuming everything goes to plan. In other words, Indivior only has four new products under development. 

Premium valuation 

Indivior’s performance has eclipsed that of Astra over the past six months. While Astra’s shares have slipped by 11.4% since the end of January, Indivior’s shares have gained a staggering 53% over the same period. 

However, these gains have left Indivior looking expensive, considering the company’s earnings are set to slide by more than 40% this year and a further 20% during 2016. At present levels, Indivior is trading at a forward P/E of 14.1 and a 2016 P/E of 17.5. City analysts believe the company’s shares will support a dividend yield of 2.5% this year. 

In comparison, Astra’s earnings per share are set to fall by around 1% this year and 3% during 2016 before returning to growth during 2017. What’s more, the group currently trades at a forward P/E of 15.6 and supports a dividend yield of 4.3%. 

The bottom line

Overall, Astra is cheaper, supports a more attractive dividend yield, and has a greater number of new treatments under development than Indivior.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »